Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

ExternalLink');" target='_blank' href="http://www.nexavar.com/">www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Bayer HealthCare Pharmaceuticals Inc.
Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals business of Bayer HealthCare LLC, a subsidiary of Bayer AG.  Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry, and combines the activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions.  Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, General Medicine, which includes Cardiology and Primary Care and Specialty Medicine, which includes Hematology, Oncology and Multiple Sclerosis. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.

About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, a targeted alpha-folate inhibitor, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing.
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... BEIJING , March 27, 2015 ... the "Company") (NYSE: CCM ), a leading ... the largest network of radiotherapy and diagnostic imaging ... announced the signing of a purchase agreement under ... wholly owned subsidiary of the Company, agreed to ...
(Date:3/26/2015)... , March 26, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... with a focus on Omega-3 therapies for cardiovascular disease ... it issued 763,752 common shares of the Corporation (the ... for the period of December 5 th , 2014 ... Convertible Notes that is due on or before April ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
Breaking Medicine Technology:Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8
... 2011 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, ... the companies have begun enrolling patients in a ... (sorafenib) tablets in combination with the oral chemotherapeutic ... treatment of patients with advanced breast cancer. This ...
... OSAKA, Japan, February 23, 2011 Takeda Pharmaceutical ... Research & Development Center, Inc. U.S., submitted a ... and Drug Administration (FDA) for an investigational fixed-dose ... the treatment of hypertension, or high blood pressure. ...
Cached Medicine Technology:Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 2Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 3Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 4Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 5Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 6Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 7Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension 2Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension 3
(Date:3/29/2015)... Youth Villages will participate in a partnership ... the feasibility of implementing a Pay for Success model ... their families. , Third Sector Capital Partners Inc. ran ... provided technical assistance throughout 2015 toward a Pay for ... awardees chosen by Third Sector. The organization’s work with ...
(Date:3/29/2015)... North American Seminars receives Texas Board ... Education Courses . , Utilizing Pilates to ... TPTA, approval # 56399TX      , The Interactive ... complex - 10.5 hours - Texas Board of Physical ... Treatment of the SI Joint - 10 hours - ...
(Date:3/28/2015)... Bellingham, WA (PRWEB) March 28, 2015 ... for athletes, recently announced the release of their new natural ... ounce and 3 ounce packages. Both options come with ... be purchased at RocketPure.com or on Amazon. Click ... product description states that the natural sunscreen is made with ...
(Date:3/28/2015)... Could genetic code determine someone’s coffee ... by researchers at the Harvard T.H. Chan School ... of the Coffee and Caffeine Genetics Consortium and ... fall, the study—one of several recent HSPH investigations of ... more than 120,000 regular coffee drinkers of European and ...
(Date:3/28/2015)... Take a bite of warm, gooey pepperoni pizza, ... into the stomach, ready to break down your meal. ... acids run amok, triggering a burning sensation in the ... 60 million Americans have heartburn at least once a ... how it can be stopped. , Heartburn or acid ...
Breaking Medicine News(10 mins):Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2
... Every Step Counts Organization in,association with Clear ... Park will continue its efforts to celebrate survivors ... host "Walk In,Her Shoes" 2008, a unique designer ... Louis and Atlanta. Designer shoes featured in "Walk ...
... CINCINNATI, Feb. 25 LCA-Vision Inc. (Nasdaq:,LCAV), a leading ... announced the opening of a LasikPlus vision center in ... in the United,States and the first LasikPlus vision center ... located in 33 states, serving 58 markets., Similar ...
... Participation in HIMSS Highlights Myriad Opportunities for Using Wireless ... to Improve Efficiency and Accuracy of Patient Care, ... leading,global provider of intelligent wireless LANs (WLANs) for enterprises ... Annual HIMSS,Conference & Exhibition, taking place February 24-28 in ...
... Healthcare Organizations Deliver Clinical ... Data Faster and Improve Productivity, ... provider of intelligent wireless LANs (WLANs) for enterprises and,service ... ) ( http://www.cardiacscience.com ), the leading provider of,cardiac monitoring, ...
... Increased Uptake of, CellCept Will Provide Effective Treatment ... ... WALTHAM, Mass., Feb. 25 Decision Resources, one of the,world,s ... that the entry and uptake of high-priced branded,agents will drive ...
... IQ for HealthVault Empowers Patients to Orchestrate Health ... ... Kryptiq, the leading provider,of next generation healthcare connectivity solutions, ... offices,and patients using Microsoft(R) HealthVault(TM), at the 2008 HIMSS,(Healthcare Information ...
Cached Medicine News:Health News:Shoe Therapy Helps Survivors Celebrate Life After Abuse 2Health News:LCA-Vision Announces the Opening of its 74th LasikPlus Vision Center in Des Moines, Iowa 2Health News:Colubris Demonstrates Wide-Ranging Mobility Solutions for Healthcare 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 2Health News:Cardiac Science Corporation Selects Colubris Networks' Wireless Solution for its Portable Electrocardiograph 3Health News:Uptake of Branded Agents Will Drive the Systemic Lupus Erythematosus Drug Market to Quadruple to $1.4 Billion in 2016 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 2Health News:Kryptiq and Microsoft to Showcase Unprecedented Connectivity Between Consumers and Their Doctors at HIMSS '08 3
... Clinical is an open platform for clinical diagnostic ... deck sizes of 75, 100, 150 and ... for your laboratory space and throughput requirements. Tecan ... to allow new applications and to evolve the ...
... maximum productivity, and proven reliability, Sorvall ... fully automatic cell washing and centrifugation ... 80-second wash cycle for stat testing, ... and standardized, reproducible procedures. High reliability, ...
Excellent all-around performance in digital format - MIC-D offers an exciting new way to observe the natural world. Multiple performance features provide new ways to enjoy microscope observation....
... model centrifuge. High throughput, refrigeration maintains ... with all windshield rotors, lifetime reproducibility, ... a remote personal computer or laboratory ... imbalance detection and shut down, armor ...
Medicine Products: